Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy by Qing Nian, Yan Lin, Jinhao Zeng, Yanna Zhang, Rongxing Liu

“…This article provides information on the roles of WT1 in the pathogenesis of different cancers and provides insights into drugs and immunotherapies targeting WT1. The goal of this work is to provide a systematic understanding of the current research landscape and of future directions for WT1-related studies.…”
Get full text

Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses by Tamana Eskandari, Yasamin Eivazzadeh, Fatemeh Khaleghinia, Fatemeh Kashi, Valentyn Oksenych, Dariush Haghmorad

“…These advancements have paved the way for lipid-based vaccines and immunotherapies through the application of nanoparticles and synthetic lipid antigens designed to boost immune responses against cancers and infectious diseases. …”
Get full text

Cytosolic DNA composition is determined by genomic instability mechanism and regulates dendritic cell-mediated anti-tumor immunity by Shayla R. Mosley, Angie Chen, David N.W. Doell, Siwon Choi, Courtney Mowat, Felix Meier-Stephenson, Vanessa Meier-Stephenson, Kristi Baker

“…Identifying highly stimulatory endogenous cyDNAs such as those in MSI CRCs will allow for optimized development of DNA-based STING agonist therapies to improve the responses of CIN CRCs with CIN to immunotherapies.…”
Get full text

Antitumor Responses of Invariant Natural Killer T Cells by Jennie B. Altman, Adriana D. Benavides, Rupali Das, Hamid Bassiri

“…Finally, we review the successes and failures of clinical trials employing iNKT cell-based immunotherapies and explore the future prospects for the use of such strategies.…”
Get full text

Comprehensive Analysis Identifies <i>THEMIS2</i> as a Potential Prognostic and Immunological Biomarker in Glioblastoma by Jianan Chen, Qiong Wu, Anders E. Berglund, Robert J. Macaulay, Arnold B. Etame

“…Glioblastoma (GBM) is a highly aggressive brain tumor characterized by its ability to evade the immune system, hindering the efficacy of current immunotherapies. Recent research has highlighted the important role of immunosuppressive macrophages in the tumor microenvironment (TME) in driving this immune evasion. …”
Get full text

New bispecific antibodies in diffuse large B-cell lymphoma by Adrian G. Minson, Michael J. Dickinson

“…These agents can be safely combined with other immunotherapies and chemotherapy, and single-arm and randomised trial outcomes promise an expanding role for this class of drugs in earlier treatment lines. …”
Get full text

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

“…With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+ regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.…”
Get full text

Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs by Christopher M. Fulkerson, Deepika Dhawan, Timothy L. Ratliff, Noah M. Hahn, Deborah W. Knapp

“…Therapies aimed at specific genetic and epigenetic targets in cancer cells as well as expanded development of immunotherapies are placing increased demands on animal models. …”
Get full text

Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy by Shixu Song, Jialing Gan, Qiuyue Long, Zhancheng Gao, Yali Zheng

“…The persistent threat of COVID-19, particularly with the emergence of new variants, underscores the urgency for innovative therapeutic strategies beyond conventional antiviral treatments. Current immunotherapies, including IL-6/IL-6R monoclonal antibodies and JAK inhibitors, exhibit suboptimal efficacy, necessitating alternative approaches. …”
Get full text

Distal muscle weakness as the main onset symptom in thymoma-associated myasthenia gravis: a case report and literature review by Xuan Wu, Xiao-tian Xu, Lin Zhou, Kai Qiao, Chong-bo Zhao, Su-shan Luo

“…The patient was finally diagnosed with MG by a significant decrement of Compound Muscle Action Potential in repetitive nerve stimuli, positive anti-acetylcholine receptor antibodies as well as the presence of a mass located in the anterior mediastinum. With subsequent immunotherapies for one month, the patient exhibited marked enhancement in muscle strength, followed by an uneventful thymectomy. …”
Get full text

Are Onconeural Antibodies a Clinical Phenomenology in Paraneoplastic Limbic Encephalitis? by Hongliang Zhang, Chunkui Zhou, Limin Wu, Fengming Ni, Jie Zhu, Tao Jin

“…The clinical importance of these conditions lies in their frequent response to immunotherapies and, less commonly, their association with distinctive tumors. …”
Get full text

Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals by Ghyda Murad Hashim, Mehdi Shahgolzari, Kathleen Hefferon, Afagh Yavari, Srividhya Venkataraman

“…Also addressed are plant-derived anti-cancer vaccines, nanoparticles, monoclonal antibodies, and immunotherapies. This review article brings to light the importance of plants and plant-based platforms as invaluable, low-cost sources of anti-cancer molecules of particular applicability in resource-poor developing countries.…”
Get full text

Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes by Paweł Karpiński, Łukasz Łaczmański, Maria M. Sąsiadek

“…Current immunotherapies are effective only in a subset of patients, likely due to several factors including defects in tumor cell antigen presentation, decreased response to immune effectors, and molecular heterogeneity of cancers. …”
Get full text

State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs by Nagla Abdel Karim, MD, Ahmed Magdy Rabea, MD, Philip C. Mack, PhD, Janakiraman Subramanian, MD, Ehab Khalil, MD, Mai Sherif, MD, Radwa Marawan, MD, Tagrid Gaafar, MD, Lobna Shash, MD, Kei Suzuki, MD, Manmeet Ahluwalia, MD, Hisham Wahba, MD, Salma Aboelela, MSc, Asrar Al Ahmadi, MD, Hamed Al Husaini, MD, Nada Mohsen, MD, Rana Khaled, MD, Neemat Kassem, MD, Hussein Khaled, MD, Noha El Said, MD, Nadia Zakhary, MD, Dina Shoukry, MD, Alaa Abdullah ElSadieque, MSc, M. Yasser Alsedfy, MSc, Shaheen Islam, MD, Hend ElSherbiny, MD, Mervat El Deftar, MD, Noha Awad, MD, Abdel Rahman Mohamed, MD, David Gandara, MD, Karen Kelly, MD, Triparna Sen, PhD

“…Key areas of concern include limited access to advanced diagnostics, such as comprehensive genomic profiling, and the underutilization of targeted therapies and immunotherapies, mainly owing to financial barriers. The meeting highlighted the importance of strengthening lung cancer screening programs, improving smoking cessation efforts, and addressing environmental risk factors like air pollution. …”
Get full text

Loading of CAR‐T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism by Felix Pfister, Lucas R. Carnell, Lisa Löffler, Philipp Boosz, Niels Schaft, Jan Dörrie, René Stein, Malte Lenz, Erdmann Spiecker, Christian M. Huber, Sami Haddadin, Carola Berking, Christoph Alexiou, Christina Janko

“…These results demonstrate that lytic cytotoxicity is retained after SPION‐functionalization and provides a basis for future site‐specific immunotherapies against solid tumors with reduced systemic adverse side effects.…”
Get full text

Low Distribution of TIM-3+ Cytotoxic Tumor-Infiltrating Lymphocytes Predicts Poor Outcomes in Gastrointestinal Stromal Tumors by Chun Zhuang, Bo Ni, Zi-Zhen Zhang, Wen-Yi Zhao, Lin Tu, Xin-Li Ma, Lin-Xi Yang, Hui Cao, Ming Wang

“…There are multiple tumor-infiltrating lymphocytes (TILs) and relevant immune checkpoints existing in gastrointestinal stromal tumor (GIST), which provides opportunities and rationales for developing effective immunotherapies. Recent studies have suggested that checkpoint TIM-3/Gal-9 plays a pivotal role on immune response in multiple tumors, similar to the PD-1/PD-L1, emerging as a potential therapeutic target. …”
Get full text

An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients by Jeffrey Babad, Riyasat Ali, Jennifer Schloss, Teresa P. DiLorenzo

“…This model should find utility as a tool to uncover the mechanisms underlying the association between reduced thymic insulin expression and T1D in humans and aid in preclinical studies to evaluate insulin-targeted immunotherapies for the disease.…”
Get full text

Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Lit... by Narciss Mobini, Rummit Dhillon, Jason Dickey, Jordan Spoon, Kaviyon Sadrolashrafi

“…By a comprehensive literature review, we intend to raise awareness about this potential skin side effect in the growing number of patients receiving targeted immunotherapies. It is crucial to have a high index of suspicion and perform timely biopsies to implement appropriate management strategies.…”
Get full text

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology by Jing Lu, Ying Zhang, Chunyan Yan, Jingwen Liu, Dan Qi, Yue Zhou, Qinwen Wang, Juechen Yang, Jing Jiang, Benhao Wu, Meiling Yang, Weiwei Zhang, Xin Zhang, Xiaoyu Shi, Yan Zhang, Kun Liu, Yongcai Liang, Chaoyang Wang, Hanyu Yang, Yuqing Gao, Yuping Sun, Ronghu Ke, Jason H. Huang, Min Wu, Hongbo Wang, Chunlei Li, Shuang Zhou, Bin Guo, Erxi Wu, Guoying Zhang

“…Despite significant advances in targeted therapies and immunotherapies, non-small cell lung cancer (NSCLC) continues to present a global health challenge, with a modest five-year survival rate of 28 %, largely due to the emergence of treatment-resistant and metastatic tumors. …”
Get full text

The Potential Impact of HNRNPA2B1 on Human Cancers Prognosis and Immune Microenvironment by Tao Huang, Gang Zhu, Fan Chen

“…HNRNPA2B1 plays a significant role in the TME and is involved in the regulation of novel immunotherapies. Its expression is significantly associated with the infiltration of macrophages, dendritic cells, NK cells, and T cells. …”
Get full text